<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00629824</url>
  </required_header>
  <id_info>
    <org_study_id>KMUH-IRB- 960047</org_study_id>
    <nct_id>NCT00629824</nct_id>
  </id_info>
  <brief_title>Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C</brief_title>
  <official_title>Efficacy and Safety of Pegylated Interferon Plus Ribavirin Combination Therapy in Treating Older Patients With Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combination therapy with pegylated interferon-alpha plus ribavirin has greatly improved the&#xD;
      treatment efficacy and is the mainstream of treatment for chronic hepatitis C infection. The&#xD;
      efficacy and safety of pegylated interferon-alpha plus ribavirin combination therapy and its&#xD;
      impact on the outcome in older patients with chronic hepatitis C deserve to be elucidated.&#xD;
&#xD;
      The purposes of this study are:&#xD;
&#xD;
        1. To evaluate the efficacy of pegylated interferon-alpha 2a plus ribavirin combination&#xD;
           therapy in older patients with chronic hepatitis C&#xD;
&#xD;
        2. To investigate the safety of pegylated interferon-alpha 2a plus ribavirin combination&#xD;
           therapy in older patients with chronic hepatitis C&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, hospital-based, case-control study enrolling 70 chronic hepatitis C patients&#xD;
      who are 65 to 80 years of age and other sex- and HCV genotype-matched 140 chronic hepatitis C&#xD;
      patients who are 50 to 64 years of age will be conducted for comparison. The 210 patients&#xD;
      chronic hepatitis C patients will receive pegylated interferon-alpha plus ribavirin&#xD;
      combination therapy. Genotype 1 infected patients will received 48 weeks of treatment and&#xD;
      genotype non-1 patients will received 24 weeks of treatment. Another 40 HCV-1 infected&#xD;
      patients who are 65-80 years of age and have a rapid virological response ( defined as&#xD;
      seronegative of HCV RNA at week 4 of treatment) will receive 24 weeks of treatment and are&#xD;
      enrolled for comparison since Jan 2008. The primary outcome measurement is sustained&#xD;
      virological response and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.</measure>
    <time_frame>1.5 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>RVR, rapid virological response, defined as HCV RNA &lt; 50 IU/mL at treatment week 4</measure>
    <time_frame>1.5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>110 naïve CHC patients who are 65 to 80 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>140 naïve CHC patients who are 50 to 64 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 HCV-1 infected patients with an RVR who are 65-80 years of age will receive 24 weeks of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon alpha and plus ribavirin</intervention_name>
    <description>pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks</description>
    <arm_group_label>A</arm_group_label>
    <other_name>PEGASYS®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon alpha and plus ribavirin</intervention_name>
    <description>pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks</description>
    <arm_group_label>B</arm_group_label>
    <other_name>PEGASYS®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon alpha and plus ribavirin</intervention_name>
    <description>pegylated interferon alpha 180 ug/week and ribavirin 1000-1200 mg/day for 24 weeks</description>
    <arm_group_label>C</arm_group_label>
    <other_name>PEGASYS®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients &gt;50 years of age&#xD;
&#xD;
          -  Patients have never been treated with traditional interferon plus ribavirin or&#xD;
             peginterferon plus ribavirin&#xD;
&#xD;
          -  Serologic evidence of chronic hepatitis C infection by an anti-HCV antibody test&#xD;
&#xD;
          -  Detectable serum HCV-RNA&#xD;
&#xD;
          -  Liver biopsy findings consistent with the diagnosis of chronic hepatitis C infection&#xD;
             with or without compensated cirrhosis (Exception: hemophiliacs in whom biopsy is&#xD;
             medically contra-indicated do not require biopsy.)&#xD;
&#xD;
          -  Compensated liver disease (Child-Pugh Grade A clinical classification)&#xD;
&#xD;
          -  Negative urine or blood pregnancy test (for women of childbearing potential)&#xD;
             documented within the 24-hour period prior to the first dose of study drug&#xD;
&#xD;
          -  All fertile males and females receiving ribavirin must be using two forms of effective&#xD;
             contraception during treatment and during the 6 months after treatment end&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with ongoing pregnancy or breast feeding&#xD;
&#xD;
          -  Present therapy with any systemic anti-neoplastic or immunomodulatory treatment&#xD;
             (including supraphysiologic doses of steroids and radiation) within 6 months prior to&#xD;
             the first dose of study drug&#xD;
&#xD;
          -  Any investigational drug 6 weeks prior to the first dose of study drug&#xD;
&#xD;
          -  History or other evidence of a medical condition associated with chronic liver disease&#xD;
             other than HCV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease,&#xD;
             alcoholic liver disease, toxin exposures)&#xD;
&#xD;
          -  Clinical evidence or history of hepatocellular carcinoma&#xD;
&#xD;
          -  History or other evidence of bleeding from esophageal varices or other conditions&#xD;
             consistent with decompensated liver disease&#xD;
&#xD;
          -  Neutrophil count &lt;1500 cells/mm3 or platelet count &lt;90,000 cells/mm3 at screening&#xD;
&#xD;
          -  Serum creatinine level &gt;1.5 times the upper limit of normal at screening&#xD;
&#xD;
          -  History of severe psychiatric disease, especially depression. Severe psychiatric&#xD;
             disease is defined as treatment with an antidepressant medication or a major&#xD;
             tranquilizer at therapeutic doses for major depression or psychosis, respectively, for&#xD;
             at least 3 months at any previous time or any history of the following: a suicidal&#xD;
             attempt, hospitalization for psychiatric disease, or a period of disability due to a&#xD;
             psychiatric disease&#xD;
&#xD;
          -  History of a severe seizure disorder or current anticonvulsant use&#xD;
&#xD;
          -  History of immunologically mediated disease, chronic pulmonary disease associated with&#xD;
             functional limitation, severe cardiac disease, major organ transplantation or other&#xD;
             evidence of severe illness, or any other conditions which would make the patient, in&#xD;
             the opinion of the investigator, unsuitable for the study&#xD;
&#xD;
          -  History of thyroid disease poorly controlled on prescribed medications, elevated&#xD;
             thyroid stimulating hormone (TSH) concentrations with elevation of antibodies to&#xD;
             thyroid peroxidase and any clinical manifestations of thyroid disease&#xD;
&#xD;
          -  Evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration)&#xD;
&#xD;
          -  Evidence of drug abuse (including excessive alcohol consumption&gt;40 g/day) within one&#xD;
             year of study entry&#xD;
&#xD;
          -  Inability or unwillingness to provide informed consent or abide by the requirements of&#xD;
             the study&#xD;
&#xD;
          -  Male partners of women who are pregnant&#xD;
&#xD;
          -  Hgb &lt;11 g/dL in women or &lt;12 g/dL in men at screening&#xD;
&#xD;
          -  Any patient with major thalassemia&#xD;
&#xD;
          -  Patients with documented or presumed coronary artery disease or cerebrovascular&#xD;
             disease should not be enrolled if, in the judgment of the investigator, an acute&#xD;
             decrease in hemoglobin by up to 4 g/dL (as may be seen with ribavirin therapy) would&#xD;
             not be well-tolerated&#xD;
&#xD;
          -  Local or Systemic malignancy unstable status&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Lung Yu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jee-Fu Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Municipal Hsiao-Kang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Antonucci G, Longo MA, Angeletti C, Vairo F, Oliva A, Comandini UV, Tocci G, Boumis E, Noto P, Solmone MC, Capobianchi MR, Girardi E. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol. 2007 Jul;102(7):1383-91. Epub 2007 Mar 31.</citation>
    <PMID>17403072</PMID>
  </reference>
  <reference>
    <citation>Hiramatsu N, Oze T, Tsuda N, Kurashige N, Koga K, Toyama T, Yasumaru M, Kanto T, Takehara T, Kasahara A, Kato M, Yoshihara H, Katayama K, Hijioka T, Hagiwara H, Kubota S, Oshita M, Haruna Y, Mita E, Suzuki K, Ishibashi K, Hayashi N. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? Hepatol Res. 2006 Jul;35(3):185-9. Epub 2006 May 4.</citation>
    <PMID>16678478</PMID>
  </reference>
  <reference>
    <citation>Thabut D, Le Calvez S, Thibault V, Massard J, Munteanu M, Di Martino V, Ratziu V, Poynard T. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol. 2006 Jun;101(6):1260-7.</citation>
    <PMID>16771947</PMID>
  </reference>
  <reference>
    <citation>Honda T, Katano Y, Urano F, Murayama M, Hayashi K, Ishigami M, Nakano I, Yoshioka K, Toyoda H, Kumada T, Goto H. Efficacy of ribavirin plus interferon-alpha in patients aged &gt;or=60 years with chronic hepatitis C. J Gastroenterol Hepatol. 2007 Jul;22(7):989-95.</citation>
    <PMID>17608843</PMID>
  </reference>
  <reference>
    <citation>Iwasaki Y, Ikeda H, Araki Y, Osawa T, Kita K, Ando M, Shimoe T, Takaguchi K, Hashimoto N, Kobatake T, Tomita M, Kawaguchi M, Kobashi H, Sakaguchi K, Shiratori Y. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology. 2006 Jan;43(1):54-63.</citation>
    <PMID>16374855</PMID>
  </reference>
  <verification_date>February 2007</verification_date>
  <study_first_submitted>February 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2008</study_first_posted>
  <last_update_submitted>September 6, 2010</last_update_submitted>
  <last_update_submitted_qc>September 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ming-Lung Yu</name_title>
    <organization>Kaohsiung Medical University Hospital</organization>
  </responsible_party>
  <keyword>chronic hepatitis C</keyword>
  <keyword>sustained virological response</keyword>
  <keyword>rapid virological response</keyword>
  <keyword>peginterferon</keyword>
  <keyword>ribavirin</keyword>
  <keyword>old age</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

